Imaginostics Joins Forces with the Prestigious Paris Saclay Cancer Cluster to Revolutionize Oncology

In a significant stride towards transforming cancer research and treatment, Imaginostics is proud to announce its inclusion in the esteemed Paris Saclay Cancer Cluster (PSCC). This collaboration marks a pivotal moment in our ongoing mission to advance the predictive, precise, and efficient treatment of cancer through innovative technologies.

Founded under the visionary guidance of French President Emmanuel Macron in June 2021, the PSCC stands at the forefront of oncology innovation. Located in the vibrant heart of the Grand Paris area, specifically in Villejuif, the PSCC fosters a unique ecosystem where researchers, clinicians, innovators, and patients converge to accelerate breakthroughs in cancer care.

Imaginostics was one of the four new organizations announced in December to benefit from the power of the PSCC ecosystem, alongside Cherry Biotech, EverImmune, and Prostperia, Imaginostics is set to benefit from an unparalleled range of resources. This includes access to experts, networks, funding, data, samples, technologies, infrastructures, training, and laboratories. Our inclusion in this dynamic biocluster is a testament to the potential of our cutting-edge oncology projects to make a profound impact on patient care.

The Paris Saclay Cancer Cluster’s comprehensive offering aligns perfectly with our commitment to developing innovative solutions that meet the urgent needs of patients battling cancer. With the PSCC’s support, Imaginostics is poised to push the boundaries of what’s possible in oncology, leveraging our expertise to contribute to a future where cancer treatment is more targeted, effective, and compassionate.

To date, the PSCC has selected and supported 31 groundbreaking oncology projects, illustrating its pivotal role in fostering industrial development and innovation in the field. Imaginostics is honored to join this vibrant community of pioneers, and we are eager to collaborate with fellow members to advance our shared goal of transforming oncology research and treatment.

For those developing innovative solutions in oncology and interested in joining this trailblazing initiative, we encourage you to learn more about the application process at the PSCC’s website.

Imaginostics’ collaboration with the Paris Saclay Cancer Cluster heralds a new chapter in our journey to revolutionize oncology. Together, we are committed to making a lasting impact on the lives of patients around the world, pushing the envelope of innovation to fight cancer with unprecedented precision and efficacy.

Stay tuned for more updates on our projects and the groundbreaking work being done at the Paris Saclay Cancer Cluster.